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Abstract
Background: Upon cellular entry retroviruses must avoid innate restriction factors produced by the host cell. For
human immunodeficiency virus (HIV) human restriction factors, APOBEC3 (apolipoprotein-B-mRNA-editing-enzyme),
p21 and tetherin are well characterised.
Results: To identify intrinsic resistance factors to HIV-1 replication we screened 19,121 human genes and identified
114 factors with significant inhibition of infection. Those with a known function are involved in a broad spectrum
of cellular processes including receptor signalling, vesicle trafficking, transcription, apoptosis, cross-nuclear
membrane transport, meiosis, DNA damage repair, ubiquitination and RNA processing. We focused on the PAF1
complex which has been previously implicated in gene transcription, cell cycle control and mRNA surveillance.
Knockdown of all members of the PAF1 family of proteins enhanced HIV-1 reverse transcription and integration of
provirus. Over-expression of PAF1 in host cells renders them refractory to HIV-1. Simian Immunodeficiency Viruses
and HIV-2 are also restricted in PAF1 expressing cells. PAF1 is expressed in primary monocytes, macrophages and
T-lymphocytes and we demonstrate strong activity in MonoMac1, a monocyte cell line.
Conclusions: We propose that the PAF1c establishes an anti-viral state to prevent infection by incoming
retroviruses. This previously unrecognised mechanism of restriction could have implications for invasion of cells by
any pathogen.
Background
Viruses usurp normal cellular processes to complete
their life cycle. Once inside the cell cytoplasm viral
RNA is reverse transcribed into single stranded cDNA
followed by double stranded (ds)DNA. The dsDNA in
cells forms a pre integration complex (PIC) which
includes viral proteins and interacts with numerous cell
components. Eventually the PIC is transported into the
nucleus for host DNA integration.
The use of small-interfering RNA (siRNA) screens has
greatly extended our knowledge of the cellular processes
hijacked by viruses for infection and the components
needed by HIV to facilitate these early steps in replica-
tion [1-4]. For example TNPO3, was identified by two
screens to be a required for a replication step in the
HIV life cycle [1,2]. TNPO3 was later shown to facilitate
nuclear import of the PIC [5].
Host cells, however, have evolved intrinsic resistance
factors to mitigate viral replication. Several host restric-
tion factors have been identified that prevent the pro-
gression of HIV replication during the early phase of the
life cycle. The best characterised of these are encoded by
the TRIM5a and the APOBEC gene families [6,7]. APO-
BECs interact with the nascent DNA during reverse
transcription [6]. TRIM5a interacts with incoming viral
capsids (CA) resulting in premature disassembly [7].
TRIM28/KAP1 has recently been shown to restrict inte-
gration of HIV-1 [8]. p21(Waf1/Cip1/Sdi1) (p21) was
identified to act during or after reverse transcription
[9,10]. SAMHD1 acts prior to integration, possibly by
degrading or preventing the accumulation of HIV DNA
[11]. Another restriction factor Tetherin (BST-2/CD317)
acts post integration to prevent viruses from leaving the
cell during the budding stage of the life cycle [12].
To detect intrinsic anti-viral restriction factors acting at
the early, post fusion stages of HIV-1 replication, HeLa-
CD4 cells were transfected with an siRNA library targeting
19,121 human genes and then challenged with an HIV-
189.6R pseudovirus carrying a GFP reporter gene (HIV-1
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gag/pol/tat and rev, HIV-2 MCR Env). The negative fac-
tors identified perform a diverse range of cellular activities.
Those with known function are involved in receptor sig-
nalling, vesicle trafficking, transcription, apoptosis, cross-
nuclear membrane transport, meiosis, DNA damage
repair, ubiquitination and RNA processing. Our screen for
anti-HIV factors can serve as a platform to understanding
the host’s adaptation viral infection.
Results
System Setup
To detect human cellular restriction factors that operate
at the early stages of HIV-1 replication, we developed a
single round infectious HIV pseudotype assay to siRNA
screen HeLa-CD4 cells. The HIV pseudotype HIV89.6R,
has an HIV-2 Env MCR (derived from the primary
isolate prCBL-23). HeLa-CD4 cells contain ectopically
expressed CD4 but naturally express the co-receptor
CXCR4. Both receptors are used by HIV89.6R to enter
cells. HIV89.6R was evaluated for tropism in HeLa-CD4
cells. Although HIV89.6R replicates efficiently on NP2-
CD4-CXCR4 cells it is restricted on HeLa-CD4 cells
(Figure 1B) while HIV8.2N grows equally well on both
cell types and was used as a positive control for viral
replication and to monitor the GFP expression and
siRNA effects (Figure 1C). The viral pseudotypes
HIV89.6R and HIV8.2N are only capable of a single round
of infection so the number of GFP expressing cells is
equivalent to virus infectious units (or focus forming
units, FFU). An increase in infectious units after siRNA
gene knockdown followed by virus challenge after 72
hours indicated rescue of viral replication.
A B
C
D
Figure 1 siRNA screen setup. 1A Screen strategy and results. 1B Infectious units/μl of HIV8.2N and HIV89.6R virus stocks following challenge on
HeLa-CD4 and NP2-CD4-CXCR4 cells. Results are mean ± SD of a representative experiment performed in triplicate. 1C GFP+ foci following virus
challenge of HeLa-CD4 cells of HIV89.6R and HIV8.2N. Green, virus; red, cells. 1D siRNA knockdown of AP2M1 and PAF1 rescues infection of HeLa-
CD4 cells by HIV89.6R compared with a negative control siRNA (CB). HIV8.2N is the non-restricted positive control. % infection: AP2M1 3.57%, PAF1
0.65%, CB 0.0004%. Green, virus; red, cells.
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To optimise the screen we used negative control siR-
NAs targeting cyclophilin B (CB; siGLO), PLK1 and
GFP. The reverse transfection protocol was almost 100%
efficient, CB protein expression was reduced by 60%, the
PLK1 siRNA (cell killer control) reduced cell number by
more than 99% and GFP siRNA reduced GFP intensity
by 67.8% (data not shown). siRNAs against the CD4
receptor and the nuclear importin TNPO3 were used to
test the effects of the siRNAs on the inhibition of non-
restricted HIV8.2N infectivity. The results show that the
infection was reduced by 95.8% and 93.0%, respectively
(Additional file 1, A1).
Primary siRNA screen
Figure 1A shows a schematic representation of the
screen results. Target HeLa-CD4 cells were transfected
in 384 well plates with a whole genome siRNA library
(19,121 human genes, four pooled siRNAs per gene, 30
nM). siRNA targeting CB served as a negative control (n
= 16 per plate). HeLa-CD4 cells transfected with
HIV8.2N served as a positive control for the GFP read-
out. The screen was performed with 30 nM total siRNA
concentration to minimise off-target effects. After 72
hours, transfected cells were challenged with HIV89.6R -
which carries a GFP reporter gene (HIV-1 gag/pol/GFP).
Five days post siRNA transfection, cells were stained
with DAPI and Cell Mask (Invitrogen) to enable seg-
mentation of GFP+ and GFP- foci. Images were col-
lected on the IN Cell 1000 microscope (GE Healthcare).
The images were quantified by IN Cell Developer soft-
ware (GE Healthcare) to generate the total cell number
and GFP+ foci per well (equivalent to FFU).
Statistical analysis was performed for each of the 61
plates. Wells containing > 3SD foci of infection com-
pared to the CB plate mean were confirmed by visual
inspection. A robust Z-score of > 3 (which equates to
a > 3SD difference from the mean; equivalent to rescue
of more than 1.2 × 103 FFU/ml) was deemed signifi-
cant (Figure 2A). Two examples (AP2M1 and PAF1) of
the ‘positive hits’ are shown in Figure 1D alongside
wells challenged with the restricted HIV89.6R and the
unrestricted HIV8.2N. The results in Figure 2 show that
192 genes increased the GFP foci by more than 3SD
from the controls (Additional file 2 contains a
AP2M1 
RTF1 
PAF1 
CTR9 
SETDB1 
DNM2 
Figure 2 Validation of screen positive results. Distribution of rescued HIV89.6R infection determined by GFP+ foci/well (left Y axis) with Z-
scores (right Y axis) for the siRNA library (open circles) compared with CB control siRNA (closed circles). AP2M1, DNM2, SETDB1 and genes
associated with the PAF1c CTR9, PAF1 and RTF1 are highlighted. GFP+ foci more than 3 SD (equivalent to 7.43 foci) from the average of control
infections are shown.
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complete list of genes and their corresponding Z-
scores, A2).
Secondary screen
Next, we performed a secondary validation screen for
183 of the 192 candidates from the primary screen.
Transfection of the original pooled siRNAs was per-
formed in triplicate and the same Z-score threshold
applied. This yielded 114 genes, equivalent to a 62.3%
validation rate (Additional file 3). Ingenuity Pathway
Analysis (IPA, http://www.ingenuity.com) was used to
analyse the 114 confirmed genes. Network, functional
and pathway analysis was carried out with the IPA soft-
ware. The identified genes are involved in a wide variety
of networks, such as cell signalling, molecular transport,
nucleic acid metabolism, cell cycle, DNA replication,
and recombination and repair. Additional file 4 sum-
marises the analysis (see also additional file 5, Table
including gene ontology (GO) terms, A5). Functional
analysis shows the participation of skeletal development,
cell signalling, molecular transport, nucleic acid metabo-
lism, cell cycle, cell-to-cell signalling and interaction,
lipid metabolism, renal and urological disease, reproduc-
tive system development, cell-mediated immune
response, DNA replication, RNA post-transcriptional
modification, recombination and repair, antigen presen-
tation and the humoral immune response. Pathway ana-
lysis reveals possible pathways in which these genes may
be involved and include the CXCR4 signalling pathway,
virus entry via the endocytic pathway, clathrin-mediated
endocytosis and dendritic cell maturation.
Validation by individual siRNAs
We chose 52 genes (either with high Z-scores or
because their functions were related) to validate with
multiple individual siRNAs. The four siRNAs from the
original screening pool were individually tested at 30
nM using the same protocol as the secondary screen. If
cell toxicity was observed, siRNA concentrations were
adjusted. This analysis revealed that 100% (52/52) of the
genes were confirmed with at least one siRNA, while
53.8% (28/52) re-scored with two or more siRNAs
(Table 1).
Four genes; COX18, DNM2, RPRD2 and SPSC2, were
re-scored with 3/4 siRNAs. There were six genes for
which transfection with all four siRNAs enhanced virus
infection. We focussed on these genes in further func-
tional analysis. Three of these, CTR9, PAF1 and RTF1,
all belong to the human PAF1 complex [13].
AP2M1 and dynamin (DNM2) restrict HIV-2 but not HIV-1
Down modulation of AP2M1 and DNM2, both involved
in endocytosis, increased infectivity of HIV89.6R by 3.1 ×
104 and 1.6 × 104 infectious unit/ml respectively (Z
score 30.5 and 7.9; Figure 2 and 2A3) and were chosen
for further validation and analysis.
We treated HeLa-CD4 cells with siRNA to AP2M1
and DNM2 and challenged with either the pseudotype
HIV89.6R or two wild type HIV-1 strains, T-cell tropic
HIV-1NL4.3wt and the dual tropic HIV-189.6wt which can
infect both T-cells and macrophages. Interestingly, Fig-
ure 3A shows that even though AP2M1 and DNM2
knockdown rescued HIV89.6R by 12.6 and 6.5 fold,
respectively there was no rescue of wild type HIV-1.
Indeed none of the four siRNAs to AP2M1 or dynamin
(DNM2) rescued HIV89.6wt or HIVNL4.3wt viruses (data
not shown). The major difference between the HIV
pseudovirus and the wild type HIV-1 viruses is that
HIV89.6R is pseudotyped with an HIV-2 Env. The Env of
the HIV-2MCR virus is a determinant of a post-entry
restriction, Lv2 [14-17]. Although HIV-1 viruses are
generally unrestricted when entering cells via an endocy-
tic dynamin dependent route [18] we have shown that if
cellular endocytosis is blocked HIV-2MCR virus is res-
cued from Lv2 restriction [14,15,17]. More specifically
we have recently shown that down modulation of
AP2M1 by siRNA or dominant negative inhibition of
DNM2 can rescue HIV-2MCR (envelope mediated) inhi-
bition by Lv2 [16,19]. Thus our results here showing
Table 1 Number of individual siRNA able to rescue HIV-1
infection in HeLa-CD4 cells.
4/4 3/4 2/4 1/4
AP2M1 COX18 ALDH8A1 BCAR1
C3orf63 DNM2 ALX3 C11orf38
CTR9 RPRD2 BCYRN1 C15orf27
PAF1 SPCS2 C11orf38 DSP
RTF1 CCDC53 EVI2B
SETDB1 ELF3 FUT1
IL1F9 GANC
LOC388955 GCNT3
MARCH8 ICAM4
MKRN3 INO80B
OPTC KCNG1
PELP1 KCNN1
POLB KLK3
R3HDML LRRC24
RAPGEF3 POP5
SHE RMI1
SLC9A3R2 SEBOX
SPAG16 SLC35B1
SNORD114-31
SNORD115-32
TMEM209
TRIM27
WSB2
ZNF761
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rescue of the HIV-2 but not HIV-1 envelope mediated
entry is consistent with these previous observations. The
identification of AP2M1 and DNM2 in our primary
screen further demonstrates the stringency of the pri-
mary screen.
SETDB1 inhibits HIV-1 replication at a step prior to
integration
Surprisingly, all siRNA targets to SETDB1 resulted in
rescue of HIV89.6R replication. SETDB1 is a histone
methyl transferase and along with heterochromatin pro-
tein 1 (HP1) and NuRD, a histone deacetylase (HDAC),
is recruited by TRIM28 (also known as KAP1, KRAB-
associated protein 1) to inhibit replication of endogen-
ous retroelements during embryonic development [20].
TRIM28 has also been reported to restrict replication of
the gamma retrovirus M-MLV in cells by inhibition of
proviral gene expression [21]. Our result was a surprise
because there is no previous evidence suggesting that
HIV-1 is targeted prior to integration. Indeed our screen
used an HIV pseudovirus capable of only a single round
of infection so genes enhancing post integration events
are unlikely to be detected. To investigate we selected
SETBD1 for further analysis.
SETDB1 had a Z-score of 6.8 in the initial screen.
Down modulation of SETDB1 enhanced the infection of
both HIV89.6R and wild type HIV-1 (8.8 × 103 and 1.7-
1.9 × 104 FFU/ml) (A3 and Figure 3B). To probe the
time point in the viral replication that was impeded by
the expression of SETDB1 proteins we PCR-amplified
total viral DNA (gag) to detect progression and comple-
tion of reverse transcription after treatment with
SETDB1 siRNA. An Alu-PCR was established to detect
integrated proviral DNA. Analysis of the effect of
A B
C
Figure 3 Analysis of selected genes. 3A AP2M1 and DNM2 siRNA knockdown rescues infection of HeLa-CD4 cells by pseudotyped HIV89.6R
and wild type HIV-189.6wt and HIV-1NL4.3wt. The y-axis denotes both the number of infectious viruses rescued (FFU/ml; left) and fold rescue
compared with the CB control (right). FFU/ml results are mean ± SD. 3B SETBD1 siRNA knockdown rescues infection of HeLa-CD4 cells by
replication competent HIV-189.6wt and HIV-1NL4.3wt (MOI 0.7). FFU/ml results are mean ± SD. 3C Knockdown of SETDB1 results in enhanced HIV-1
RT products - total (0-16 hr pi) and integrated proviral DNA (Alu-gag, fold change, 48 hr pi). Control wells containing inhibitors were negative for
HIV-1 DNA. HIV-1 DNA copies are normalised to genomic GAPDH and presented per million cells. Results are mean ± SD of a representative
experiment performed in duplicate.
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SETDB1 knockdown on the levels of total HIV-1 DNA
showed no apparent difference while there was a 3.2
fold increase in integrated proviruses (Figure 3C).
Thus our results strongly suggested that SETDB1 is
also involved in inhibition of HIV-1 replication. Consis-
tent with this hypothesis Allouch et al. report that
TRIM28 indeed restricts replication of HIV-1 integra-
tion through recruitment of HDAC [8]. The molecular
details will be worth pursuing.
PAF1 complex expression renders cells in an antiviral
state
A striking observation is that enhancement of infection
results after independent knockdown of 3 components
of the PAF1 complex (PAF1c) [22-24], PAF1, CTR9 and
RTF1 (A3, Z scores from the initial screen of 4.4, 3.3
and 8.5 respectively). These were chosen for further
analysis and 2 additional components of the PAF1 com-
plex, CDC73 and LEO1, were included in subsequent
investigations.
To further confirm the specificity of the siRNAs we
tested each of the PAF1c siRNAs for their effect on
expression of each other. We find that the siRNA to
PAF1, CTR9 and RTF1 reduced their own mRNA levels
and not each other’s (data not shown).
Figure 4A shows that in addition to PAF1, CTR9 and
RTF1 identified in the screen, knockdown of the
remaining 2 components of the PAF1c, LEO1 and
A
C
B
D E
Figure 4 Anti-viral activity of the PAF1 complex. 4A CDC73, CTR9, LEO1, PAF1 and RTF1 siRNA knockdown rescues infection of HeLa-CD4
cells by HIV89.6R pseudotype. CDC73 and LEO1 were additionally deconvoluted and 4/4 and 3/4 siRNA respectively were able to rescue HIV-189.6R
infection in HeLa-CD4 cells. The y-axis denotes both the number of infectious viruses rescued (FFU/ml; left) and fold rescue compared with the
CB control (right). FFU/ml results are mean ± SD. 4B PAF1c siRNA knockdown rescues infection of HeLa-CD4 cells by replication competent HIV-
189.6wt and HIV-1NL4.3wt (MOI 0.7). FFU/ml results are mean ± SD. 4C Knockdown of PAF1 and CTR9 rescues HIV-2CBL-21, HIV-2MCR, SIVAGM (African
Green Monkey; 3084), SIVMAC (Macaque; 32H) and SIVSM (Sooty Mangabey; B670) infection. Results are fold increase compared with CB and are
mean ± SD of at least 3 representative experiments. 4D Knockdown of PAF1, CTR9 and RTF1 in MM1 cells results in rescue of HIV-1 infection of
replication competent HIV-189.6wt. Results are mean ± SD of a representative experiment. Transfection of MM1 cells with PAF1 siRNA results in
partial knockdown. 4E Western blot analysis of primary cell lysates (CD4+ T cells, monocytes and macrophages (MDM)) showing protein levels of
PAF1.
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CDC73 also rescued infection of HIV89.6R. LEO1 and
CDC73 were false negatives in the primary screen. Next
we tested the effect of inhibition of expression of these
factors against the wild type viruses HIV-1NL4.3wt and
HIV-189.6wt. Figure 4B shows that knockdown of any
one of all five components of the PAF1c rescued infec-
tion of wild type viruses by 1.7-7.2 fold (equivalent to
6.2 × 103-2.7 × 104 FFU/ml).
To determine whether the anti-viral effect observed
was restricted to HIV-1 we tested for activity against
HIV-2 and SIV isolates. We used siRNA to two PAF1c
components, PAF1 and CTR9. Figure 4C shows that
inhibiting expression of either of these proteins resulted
in rescue of HIV-2 (CBL-21 and MCR) and SIV (African
Green Monkey, Macaque and Sooty Mangabey) by 4-10
fold.
We wanted to test if there was an effect of PAF1c in
cells of more physiological relevance to HIV-1 infection.
Figure 4D shows that treatment of the differentiated
monocytoid cell line MonoMac1 (MM1) with siRNA
targeting PAF1, CTR9 and RTF1 resulted in rescue of
HIV-189.6wt (2.5-4.7 × 104 FFU/ml, 2.5-4 fold). In Figure
4E Western blot analysis reveals that PAF1 is expressed
in primary CD4+ T-cells, monocytes and monocyte
derived macrophages. Attempts however to knock down
expression in these cell types resulted in cytotoxicity.
There are a number of recognised steps in the early
phase of retroviral replication that restriction factors
might target. To determine the time point that viral
replication was blocked due to the action of PAF1c pro-
teins we PCR-amplified viral strong-stop DNA (ssDNA)
to detect the initiation of reverse transcription and full
length viral cDNA to detect progression and completion
of reverse transcription after treatment with various siR-
NAs. Alu-PCR was used to detect integrated proviral
DNA. Figure 5A shows that knockdown of PAF1, CTR9,
and RTF1 resulted in enhanced viral ssDNA levels as
well as full length cDNA of 3-7 fold more than CB trea-
ted cells indicating that a block to reverse transcription
was relieved. An alternative explanation is that RT pro-
ducts may be less susceptible to degradation. There was
also enhanced proviral integration (Alu-PCR) of full
length cDNA transcripts (Figure 5A). Thus our data
support the conclusion that the expression of the PAF1
complex induces an anti-viral state which results in
blocking viral replication during the early events from
post entry to integration of proviral DNA. To further
test this hypothesis we made an HA-tagged expression
construct of PAF1, transfected it into HeLa-CD4 cells
and challenged with HIV-189.6wt after 24 hours. Figure
5B shows Western blot analysis of transfected cells
expressing the expected HA-tagged PAF1 (PAF1-HA)
construct at 110 kDa. The level of endogenous PAF1
(80 kDa) is similar to the vector control (pmOrange-
C1). Figure 5C shows that even though the transfection
efficiency was moderate (30% by visualisation of a simul-
taneously transfected GFP plasmid; data not shown)
inhibition of HIV-189.6wt was observed. We further ana-
lysed the levels of inhibition of various stages of reverse
transcription and integration of proviral DNA. Figure
5D shows a reduction of all viral transcripts and pro-
virus. Early and late RT products are decreased by 6.3
and 2.8 × 105 copies/106 cells, respectively, while there
are 7.7 × 103 fewer integrated proviruses/106 cells in
samples that contain higher amounts of PAF1.
Thus our data so far support a role for the PAF1c in
the innate defence of host cells against viral infection.
We sought to gain some insight into the mechanism of
PAF1c’s antiviral action. PAF1c activity has been impli-
cated in a number of cellular processes including gene
expression and transcription, mRNA elongation and sta-
bility and cell cycle control [22].
We tested whether the cell-cycle arrest activity of
PAF1 could account for the rescue of infectivity
observed. PAF1 knockdown can result in early entry
into S phase and later transition out of G2 phase [25].
Knockdown of PAF1 therefore would have the same
outcome as the expression of the viral gene vpr which
induces cell-cycle arrest at G2/M phase [26] and facili-
tates viral replication. Figure 6 demonstrates however
that in the target cells used in this study down modula-
tion of PAF1 does not affect cell cycling.
PAF1 is also suggested to be involved in mRNA stabi-
lity, surveillance and degradation. It directly interacts
with SKI8 (WDR61) which forms a complex with SKI2
and SKI3 [24]. WDR61 was included in subsequent fol-
low up experiments and weak rescue of infection was
observed (2 fold, not shown). In yeast the SKI complex
is required for 3’-5’ mRNA decay in exosomes which are
regions in the nucleus and cytoplasm that specialise in
RNA degradation [22,27]. Finally, PAF1 is known to be
involved in transcription of DNA and elongation of
mRNA through its association with RNA polymerase II
during these processes [28]. It is also required for
mono-ubiquitination and methlylation of histones which
affect gene expression [29]. Indeed it has been shown
recently [30] that PAF1 along with P-TEFb, AF9, AFF1,
AFF4, ELL and ENL is recruited to the HIV LTR by Tat
for optimal promoter activation. The pseudovirus used
in our screen is only capable of single round of infection
so it is unlikely that post-integration events are detected.
Regardless we confirmed that PAF1 was not suppressing
viral gene expression. qPCR analysis of viral genes after
treatment of cells with siRNA to PAF1, CTR9 and RTF1
did not result in enhanced expression of viral gene tran-
scripts (data not shown). Thus we hypothesised that
PAF1c’s action was through the expression of anti-viral
factors. We tested whether PAF1c induces an anti-viral
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state through activation of transcription of known anti-
HIV factors. Following treatment of HeLa-CD4 cells
with PAF1 siRNA, the mRNA levels of p21, APO-
BEC3G, Tetherin, TRIM5a, SAMHD1 and TREX1 were
determined by qPCR. No difference was seen in the
expression of these restriction factors when compared
with untreated cells (data not shown) suggesting that
PAF1 does not exert its anti-viral activity through the
action of these known restrictive genes.
We conclude that PAF1c induces an anti-viral state in
cells and inhibits infection of HIV-1, 2 and SIV by
blocking progression of the early events of infection
during reverse transcription and up to integration. Our
data suggest that the anti-viral effect of PAF1 is not
mediated through control of the cell cycle, enhancement
of expression of viral transcripts, enhancement of viral
genome stability or enhancement of transcription of
known anti-viral restriction factors such as p21.
In summary we report here the results of an siRNA
screen to identify restriction factors to HIV-1 replication
by knockdown of expression of 19,121 human genes.
We identified 114 genes that affect a wide range of cel-
lular activities. Here we specifically characterised the
involvement of AP2M1, DNM2, SETDB1, PAF1, CTR9
and RTF1 in defence against retroviral invasion.
Discussion
A fairly comprehensive picture of the positive interac-
tions between HIV-1 and host cell proteins has been
established in recent years using siRNA screens that
reveal how HIV-1 exploits the host cellular machinery
[1-4]. Here, we report 114 factors which, in contrast to
positive factors, are involved in intrinsic immunity to
establish an anti-viral attack in human cells. In this
paper we refer to intrinsic immune restriction factors as
cellular factors that are constitutively expressed or can
A
CB D
Figure 5 5A Knockdown of PAF1, CTR9 and RTF1 results in enhanced HIV-1 RT products - early and late (0-16 hr pi) and proviral DNA
(Alu-gag, 48 hr pi). Control wells containing inhibitors were negative for HIV-1 DNA. HIV-1 DNA copies are normalised to genomic GAPDH and
presented per million cells. Results are mean ± SD of a representative experiment performed in duplicate. 5B Transfection of a PAF1-HA
expression construct into HeLa-CD4 cells results in increased levels of PAF1. The PAF1-HA clone possesses an HA and an orange tag (~30 kDa,
accounting for the 110 kDa band detected). 5C Over-expression of PAF1-HA resulted in a decrease in FFU/ml following challenge with HIV-
189.6wt. Results are representative of multiple experiments and are mean ± SD. 5D Over-expression of PAF1-HA results in decreased RT products -
early and late (8 hr pi) and proviral DNA (integrated, 48 hr pi). HIV-1 DNA copies are normalised to genomic GAPDH and presented per million
cells. Results are mean ± SD of a representative experiment.
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be generated in cells in the absence of help from other
arms of the immune system. Such factors however are
unlikely to act in isolation of the immune system and
may indeed be the initial trigger for innate and adaptive
immune responses in the host. The proteins identified
with known functions are associated with a vast array of
cellular processes such as receptor signalling, vesicle
trafficking, transcription, mRNA processing, DNA/RNA
surveillance, cross-nuclear membrane transport and
ubiquitination.
In our screen individual silencing of 114 genes rescued
infectivity of HIV-1 by more than 103 FFU/ml and for
some genes as many as 2 × 105 infectious units/ml (1.6-
12.6 fold). The 52 most potent siRNAs ‘hits’ were
further validated using 4 unpooled siRNAs. Rescue of
viral infection by 2 or more of the 4 siRNAs was
observed for 28 genes. Of these, AP2M1, DNM2, CTR9,
PAF1, RTF1 and SETDB1 were further characterised for
inhibition of HIV infection.
At the time of starting this screen only APOBEC3G/F
and rhesus macaque TRIM5a proteins were known as
factors that restrict HIV-1 replication. APOBECs are
packaged into virus particles in the producer cells but
act on the next round of infection in the new target cell
[6]. The HEK 293T cells used to produce the pseudo-
virus in our screen do not express APOBECs [6] so
identification of these proteins was not expected.
Neither did we identify TRIM5a because it is a species
specific restriction factor and the human protein does
not significantly affect HIV-1 [7,31]. Since the screen
was completed two other factors have been reported;
p21 acts during reverse transcription and is active in
stem cells, macrophages and CD4+ lymphocytes
[9,10,32] while SAMHD1 expression is confined to den-
dritic and myeloid lineage cells [11]. Tetherin, which
acts at the late phase of the viral life cycle prevents viral
budding [12], was not identified in this screen because
we probed the siRNA library with an HIV pseudotype
that is infectious for only a single round to the integra-
tion of provirus and GFP expression.
Using a simple model of viral restriction, intrinsic
restriction factors can be loosely divided into; detectors
of invasion, messengers, mediators and effectors that
either prevent infection of the virus or, in the case of
interferon (IFN) signalling, alert neighbouring cells. IFN
activation of the JAK-STAT pathway ultimately results
in the expression of anti-viral genes. For example the
APOBEC and TRIM gene families are induced by type I
IFNs [33].
After entry into the cell cytoplasm HIV-1 uncoating
involves the disassembly of the viral matrix (MA) and
capsid (CA) and release of the genomic RNA and the
associated proteins. Thus these viral components could
potentially be seen by the host cell as ‘non-self’ mole-
cules. Pattern Recognition Receptors (PRRs) or viral sen-
sors recognise distinct pathogen associated molecular
patterns (PAMPs). For example, recently TRIM5a was
shown to be a PRR that recognises the viral CA even-
tually resulting in immune signalling and AP-1 and NF-
B activation [34]. Of similar interest, silencing of
COX18 (a cytochrome c oxidase assembly protein)
resulted in rescue (3.3 fold). COX18 is essential for the
production of COX2 (PTGS2) [35] whose expression is
attenuated by TRIM5a knockdown [34]. It seems unli-
kely that COX18 itself is a direct PRR. It is more plausi-
ble that COX18 is an essential downstream component
that through its interaction with COX2 may commission
or interact with one or more ‘effectors’ of restriction.
During and after CA disassembly the viral nucleic
acids and those produced during reverse transcription,
RNA fragments, DNA and DNA:RNA hybrids may
become exposed to cytoplasmic PRRs. Proteins that
interact with nucleic acids might also play a role in pat-
tern recognition. Our screen did not identify any of the
classical RNA-recognising PRRs such as toll like recep-
tors TLR3, 7 or 8 or RIG-1 like receptors RIG-1 or
MDA-5 [36]. The best characterised DNA receptor DAI
(DNA dependent activator of IFN regulatory factors)
responds to adenoviral DNA [37]. In this screen silen-
cing of POLB polymerase (DNA directed) rescued viral
infection (3.5 fold). POLB rescue was validated with 2
individual siRNAs. POLB is involved in DNA damage
repair and performs base excision repair required for
Figure 6 Silencing of PAF1 does not affect cell cycle
progression. HeLa-CD4 cells transfected with PAF1 or CB siRNA
were compared to nocodazole (NOC) treated controls. Cell cycle
profiles were determined by flow cytometric analysis of PI-labelled
cultures. Western blot confirms PAF1 silencing compared to CB
control.
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DNA maintenance, replication, recombination [38].
Interestingly, POLB is specifically up regulated after
infection of cells with human herpes virus 16.
Once PAMPS are engaged multiple signalling cascades
are activated and establish an anti-viral state [39]. One
potent hit IL1F9, an interleukin cytokine, is switched on
by IFNg. Interestingly expression of this gene is also
induced after herpes simplex virus infection-1 [40]. Sig-
nal induced antiviral responses will also use de novo
transcription and translation to establish an anti-viral
environment. Three transcription factors ALX3, ELF3
and PELP1 (3, 4 and 3.4 fold, validated 2/4 siRNAs)
identified in the screen could be involved in this
process.
The screen identified a number of genes that are
involved in ubiquitination of proteins. Conjugation of
the ubiquitin monomer to proteins is mediated by
three families of enzymes; E1, E2 or E3 substrate speci-
fic ubiquitin ligases [41]. E3 enzymes are critical and
interact with both E2 and substrate. Generally, ubiqui-
tination leads to the degradation of proteins by the
proteasome. In viral restriction ubiquitination could be
involved in the degradation process of either viral pro-
teins or recycling of restriction proteins. The process
of ubiquitination is involved in TRIM5a mediated
restriction [7]. TRIM5a has E3 ligase activity. When E2
binds to the RING domain E3 ligase activity of
TRIM5a transfers the ligase from E2 to TRIM5a [42].
HIV-1 Vif appears to use ubiquitination as a means of
preventing the action of APOBEC proteins, by target-
ing the Cul5-elongin B elongin C-Rbx ubiquitin ligase.
This results in the polyubiquitination of APOBEC3G
which is then degraded by proteosomes [43-47]. A
strong ‘hit’ in our screen was the E3 ubiguitin ligase
MARCH8 (RNF178, MIR) [48] whose knockdown
resulted in rescue (4.6 fold and 2/4 unpooled siRNA).
A second strong hit was MKRN3 (markorin 3, ring fin-
ger protein, 3) where 2 individual siRNAs rescued
infection (4.7 fold). Silencing of RNF19A, TRIM25 and
TRIM27, which all belong (or are related) to E3 ligases
also rescued infectivity (3-3.5 fold between 1 × 103 and
3 × 103 FFU/ml). Interestingly TRIM25 is essential for
RIG-1 mediated IFNb production and antiviral activity
[49]. However of the latter three genes only TRIM27
was validated with individual siRNA with only 1 out of
4 siRNAs confirming the restriction phenotype. Addi-
tionally knockdown of WSB2, a bridge-protein which
connects substrate-binding domains and E3 ubiquitin
protein ligases had a modest rescue (3.2 fold, 1 of 4
individual siRNA).
Nuclear import
Once production of the viral cDNA is complete it must
be transported to and enter the nucleus through
specialised nuclear pores using host cell transport
mechanisms [50]. CA appears to remain associated with
the PIC for some time following its production [51,52]
but disassociates from the reverse transcription complex
prior to nuclear entry [53]. Nuclear trafficking is likely
to be another “check point” for the host cell. A trun-
cated protein CPSF6 (cleavage and polyadenylation fac-
tor) a member of the S/R family protein impairs nuclear
entry of PIC [54]. This restriction can be overcome by
CA mutants. In our study invalidation of NPIP (nuclear
pore complex interacting protein) resulted in enhanced
infection. The function of NPIP is not clear, though it
co localises with NUP62, a protein needed for HIV PIC
transport from cytoplasm to nucleus [2].
RNA species
We might expect that some retroviral elements would
be involved in anti-viral defence. Friend-virus-suscept-
ibility factor (Fv-1) a gag region of an endogenous retro-
virus [55], restricts murine leukaemia virus (MLV) at a
stage after cellular entry and before integration [56].
MLV CA is the target for Fv-1 [57-59]. We did not
identify endogenous retroviral genes in this screen.
However BCYRN1 which is believed to be retroposition-
ally generated [60] was identified (5.8 fold, validated 2/
4). BCYRN1 belongs to a family of interspersed repeti-
tive DNA sequences and encodes a neural small
untranslated non-messenger RNA. The specific neuronal
expression of BCYRN1 is intriguing. Immune privileged
sites such as the brain may rely more heavily on innate
immune factors to prevent viral infection. The tissue
specificity of BCYRN1 implies that it is unlikely to play
a role in HIV-1 pathogenesis.
Genes with no obvious role
A number of genes that currently have no tentative
functional role in retroviral defence were identified in
the primary screen and validated with at least 2 indivi-
dual siRNAs: SPSC2 (removes signal peptides from pro-
teins as they translocate into the endoplasmic reticulum
lumen), R3HDML (a serine protease inhibitor), SPAG16
(a component of microtubules) and RAPGEF3 (Rap gua-
nine nucleotide exchange factor 3). OPTC is a protein
that is associated with the extracellular matrix in the
eye. ALDH8A1 is an aldehyde dehydrogenase and
LOC388955 (PREL1 domain-containing protein 1) is a
mitochondrial pseudogene. A functional role cannot be
precluded as genes are frequently found to play a practi-
cal role in cellular processes far removed from those
with which they were originally associated. Several
genes, C3orf63, RPRD2, C11orf38, SLC9A3R2 and SHE
had no identified function. Further studies on these
genes may shed light on currently poorly understood
biological processes.
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Endocytosis genes AP2M1 and DNM2
Some factors identified in our screen might have been
predicted: AP2M1 and DNM2, two components of the
endocytic pathway were identified in the primary screen
to restrict infection of cells by the pseudovirus but not
by wild type HIV-1 viruses. This observation can be
explained - we previously showed HIV-1 and 2 viruses
can be blocked post-entry by a restriction factor Lv2 but
only if the virus was delivered to the cytoplasm using a
specific endocytic route mediated by an HIV-2 virus
MCR envelope [14,16,17]. The entry route is specific to
the HIV-2 envelope because pseudoviruses with VSV-G
are rescued [15]. We recently showed that blocking
entry of HIV-2 MCR virus by an AP2M1/DNM2 depen-
dent route rescued Lv2 restriction. Unlike the wild type
HIV-1 viruses, the HIV-1 pseudovirus used in our
screen was generated with an Env derived from HIV-2
MCR. So inhibition of the pseudovirus (but not the wild
type HIV-1) would be expected to be rescued by siRNAs
to AP2M1 and DNM2.
Other factors involved in endocytosis will be interest-
ing to probe with respect to the Lv2 restriction.
CCDC53 (coiled-coil domain containing protein), a
component of the WASH complex, is present on the
surface of endosomes and recruits the Arp2/3 complex
for actin polymerisation [61]. Two GTPases (or asso-
ciated proteins) were identified: RAPGEF3 (Rap guanine
nucleotide exchange factor 3) and RAB37 (small GTPase
that regulates vesicle trafficking) and knockdown of
either resulted in a 3.7 or 2.8 fold rescue. It will be
interesting to further evaluate their role in Lv2 restric-
tion. However, apart from vesicle trafficking, GTPases
regulate a myriad of cellular functions including signal
transduction and cytoskeletal organisation.
SETDB1
We did not predict that silencing of SETDB1 (SET
domain, bifurcated 1) would rescue replication of
HIV. SETDB1 is involved in TRIM family protein
TRIM28 (also known as KAP1) restriction of both
exogenous MLV and endogenous retrovirus expression
post integration in murine cells [21]. SETDB1, a his-
tone methlytransferase, the NuRD histone deacetlyase
complex (HDAC) and heterochromatin associated pro-
tein HP-1 are targeted to proviral DNA by TRIM28 to
repress transcription. Furthermore, when transfected
into human cells, SETDB1 increases HIV-LTR trans-
activation in conditions where Tat levels were subopti-
mal [62] but no function in the viral life cycle prior to
integration had been previously described. Our screen
with single round pseudotype virus should only iden-
tify genes involved in the early phase in HIV replica-
tion and not those post integration. Surprisingly,
SETDB1 silencing rescued wild type HIV-1 replication
by almost 2 × 104 FFU/ml (4.6 fold). Indeed all 4 siR-
NAs individually silencing SETDB1 resulted in viral
rescue and was a gene among our most significant
‘hits’. Upon further investigation we found that there
was a small increase in reverse transcripts and that
there was a relatively strong increase in integrated
proviral DNA. Recently, Allouch et al. described a
similar phenotype for restriction by TRIM28 through
recruitment of HDAC [8]. It will be interesting to
probe the molecular details of this interaction in
greater depth.
PAF1 complex expression renders cells restrictive to
lentiviral infection
Our validation of the PAF1c showed that all of its
known components are important for the observed
restriction. PAF1c expression restricts HIV-1, 2 and SIV.
It restricts infection of a monocytic cell line and is
expressed in primary CD4+ T cells, monocytes and
macrophages. The restriction results in fewer viral tran-
scripts both in the early and late stage of infection. It
also results in less integrated proviral DNA. We are not
sure however if this phenotype is due to PAF1’s direct
action on replicating virus or if its action is through
activation of expression of one or more unknown
restriction factors.
A role for PAF1 in the cell cycle has been recently
demonstrated [25] and studies using an in vitro disas-
sembly model have suggested that uncoating requires
cell cycle dependent host cell factors [63]. However the
cell cycle was unperturbed by inhibition of PAF1 expres-
sion in the Hela-CD4 cells we used in the screen sug-
gesting that PAF1’s cell cycle activity is not involved in
this restriction.
There are two possibilities for the action of PAF1c in
viral restriction: First, PAF1 interacts with RNA poly-
merase II and is proposed to be involved in transcrip-
tion, elongation and stability of mRNA, surveillance and
degradation [24]. Indeed a large quantity of PAF1c is
located in the nucleus so it is also possible that its activ-
ity in gene transcription may enhance expression of
anti-viral factors, some of which are already ‘hits’ in our
primary screen. Additionally we have excluded a role for
APOBEC3G, TRIM5a, p21, tetherin and the recently
described SAMHD1.
Second, it has also been demonstrated that SKI8
(WDR61) interacts with the PAF1c [24]. SKI8 is also
part of the SKI complex which is involved in mRNA
decay [24,27]. Given the ability of PAF1/SKI8 to interact
with DNA and RNA and the localisation of both these
components in the cytoplasm it is possible that PAF1c/
SKI8 could act as a PRR. DNA:RNA hybrids or degrad-
ing RNA genomes are possible targets. To distinguish
between the two possibilities of PAF1’s action it may be
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of use to determine which genes are enhanced in the
presence or absence of PAF1 using gene array analysis.
Conclusions
In summary we describe the identification of 114 genes
that are involved in restriction of HIV replication during
the early stages of the viral life cycle. Preliminary char-
acterisation of 6 genes AP2M1, DNM2, CTR9, PAF1,
RTF1 and SETDB1 confirms their biological role in ret-
roviral restriction. This preliminary characterisation
attests to the robustness of the primary screen. It is
improbable that the genes identified evolved in resis-
tance to HIV-1 infection. It is more plausible they are
active against other viruses or pathogens that invade
host cells and will be a platform for a general under-
standing of innate immune or intrinsic defence against
invasion of known and emerging pathogens. Variation in
the expression patterns and polymorphisms in these
genes may lead to an understanding of the reasons why
some individuals are more or less susceptible to specific
infectious diseases.
Methods
Cells
Culture of HEK 293T, HeLa-CD4, NP2-CD4-CXCR4,
MonoMac 1 (MM1) and C8166, and their optimal cul-
ture conditions, have been described previously
[17,64,65]. Peripheral blood mononuclear cells (PBMC)
were prepared from seronegative donors by density-gra-
dient centrifugation (Lymphoprep, Axis-Shield). CD4+ T
lymphocytes were isolated using CD4 Microbeads
according to manufacturer’s instructions (Miltenyi Bio-
tech). Monocyte-derived macrophages (MDM) were pre-
pared by adherence as described previously [66], except
that cells were harvested (for monocyte preparations)
and replated at 2 × 106 cells/ml following the initial
overnight incubation, and left to differentiate for 7-14
days in RPMI 1640 supplemented with 20% autologous
human serum and 20 ng/ml macrophage colony stimu-
lating factor (M-CSF; R&D Systems).
Plasmids and virus production
The expression plasmid for PAF1 was generated by PCR
amplifying the open reading frame from HeLa-CD4
cDNA which was subcloned into the pmOrange-C1 vec-
tor (Clontech). Primers are available upon request.
Infectious molecular clones for wild type (wt) HIV-
189.6wt and HIV-1NL4.3wt were obtained from the Centre
for AIDS Research (NIBSC, UK). Restricted pseudotyped
virions (HIV89.6R) were generated by combining the
transfer vector pCSGW with the restrictive HIV-2 envel-
ope MCR [16,17] and the core construct p8.91-89.6gag.
For the non-restricted viral particles (HIV8.2N), we used
MCN Env and p8.2-89.6 core, where the gag fragment
from p8.91-89.6gag was transferred into pCMVΔ8.2
according to the method described [67]. Virus stocks
were prepared from infectious full-length and chimeric
HIV clones by polyethylenimine (Polysciences) transfec-
tion of HEK 293T cells. SIV and HIV-2CBL-21 stocks
were grown in C8166 cells.
siRNA screen
The screen was performed using the siRNA library
(QIAGEN, the Human Whole Genome siRNA Set V4.0)
which enables gene silencing studies of 19,121 genes
from the RefSeq database (NCBI handbook). HeLa-CD4
plated at 600 cells/well in a 384-well plate were trans-
fected with 30 nM siRNA from the library or control
siRNA PPIB (cyclophilin B, referred to as CB) using
HiPerfect (QIAGEN) and the CyBio Vario (CyBio, Ger-
many) liquid handling system. The system was opti-
mised using siRNAs to CB and GFP. The siRNAs
against receptor CD4 and the nuclear importin TNPO3
reduced infectivity of HIV8.2N by 95.8% and 93.0%,
respectively.
Plates were incubated for 72 hr before challenge with
HIV89.6R (MOI 0.7 on NP2-CD4-CXCR4). 48 hr post
virus challenge, GFP expressing cells were recorded by
the IN Cell Analyzer 1000 automated imaging system
and analysed by IN Cell Developer software (GE Health-
care). Wells containing a GFP+ foci Z-score > 3 relative
to the CB control (n = 16 per plate) were confirmed by
visual inspection. 183/192 hits from the original screen
were retested in triplicate. The top 52 hits were then
further validated with four individual siRNAs per target.
Targeted proteins rescuing infection by more than two
out of four deconvoluted siRNAs were considered vali-
dated hits.
siRNA transfection and infection with replication
competent virus
HeLa-CD4 cells were seeded at 6.3 × 104 cells/well in 6-
well plates. 72 hr after siRNA transfection (15 nM
PAF1, CTR9, RTF1, LEO1/7.5 nM CDC73/30 nM all
other siRNA), cells were challenged with HIV-189.6wt
and HIV-1NL4.3wt (MOI 0.2) for up to 5 hr. 1 hr prior to
viral challenge, inhibitors (Raltegravir (1 μM), AZT (100
μM), SCH-D (1 μM) and AMD3100 (250 nM)) were
added to control wells. Infection was assessed after 24-
48 hr by intracellular p24 staining, real-time quantitative
PCR (qPCR) or mRNA analysis.
Western blot
SDS-PAGE separated cellular proteins, immobilised on
Hybond-P PVDF membrane (GE Healthcare) were
detected with the primary rabbit polyclonal antibody
against (RbpAb-) PAF1, RbpAb-GAPDH and rat pAb-
tubulin (Abcam) and a secondary horseradish peroxidise
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conjugated goat anti-rabbit/rat antibody (Promega). Pro-
teins were visualised using a chemiluminescence kit
(ECL, GE Healthcare).
In situ immunostaining for p24 antigen
Infected cells were fixed with cold (-20°C) methanol:
acetone (1:1), washed with PBS then immunostained for
p24 using mouse anti-HIV-1 p24 monoclonal antibodies
EVA365 and 366 (NIBSC) (1:50) or anti-HIV-2 patient
human plasma (1:1000) (to detect HIV-2 and SIV
infected cells), as previously described [68]. Infected
cells were blue (regarded as foci of infection (FFU/ml))
and quantitated by light microscopy.
First round Alu-gag PCR
DNA was extracted at various time points after infection
with the QIAamp DNA Blood Mini Kit (QIAGEN).
Integrated HIV-1 DNA was measured by nested PCR, as
previously described [69].
qPCR for HIV-1 DNA
The isolated DNA was subjected to qPCR to determine
the number of early (negative strand strong stop) and
late (gag) transcripts, normalised for cell number by
genomic GAPDH as previously described.
cDNA synthesis and mRNA analysis
Total HeLa-CD4 RNA was extracted an RNeasy Plant
Mini Kit (QIAGEN) and cDNA was synthesised with
Superscript III First Strand Synthesis System (Invitrogen),
according to manufacturer’s instructions. The cDNA
produced was subjected to qPCR as described [69].
Transfection of suspension cell lines
siRNA transfection of MM1 cells was performed using
the AMAXA Nucleofector Kit V (Lonza Cologne AG)
according to manufacturer’s instructions. 48 hr follow-
ing viral challenge, 20 ng/ml of phorbol 12-myristate
13-acetate (PMA) was added to induce cellular adher-
ence prior to intracellular p24 staining.
Cell cycle analysis
HeLa-CD4 cells were transfected with PAF1 or CB
siRNA for 48 hr, or treated with nocodazole (40 ng/ml;
Sigma) for 18 hr before cells were harvested. Cells were
fixed with ice-cold 70% ethanol, washed and pelleted.
Cells were RNaseA-treated (100 μg/ml; Sigma), stained
with propidium iodide (50 μg/ml; Sigma) and analysed
by flow cytometry (LSRII, BD Biosciences).
Additional material
Additional file 1: Efficiency of siRNA knockdown on HIV infection.
siRNA knockdown of the HIV receptor CD4 and nuclear importin TNPO3
inhibits infection of HIV-18.2N by 95.8% and 93% respectively compared
with CB control siRNA. Green, virus; red, cells.
Additonal file 2: Results of primary screen with Z-scores. Positive
results from primary screen are listed. Z-scores are given for all hits
greater than 3SD from CB control siRNA.
Additional file 3: siRNA knockdown of 114 genes rescues HIV
infection. Infection of HIV89.6R pseudotyped virus was rescued in HeLa-
CD4 cells following siRNA knockdown of 114 genes. The y-axis denotes
both the number of infectious viruses rescued (focus forming units/ml,
FFU/ml; left) and fold rescue compared with the CB control (right). FFU/
ml results are mean ± SD.
Additional file 4: Pathway analysis of most potent screen hits.
Ingenuity Pathway Analysis (IPA http://www.ingenuity.com) was
performed on the validated screen hits showing the functions, if known,
associated with the most potent.
Additional file 5: Network, functional and pathway analysis. A list of
114 confirmed factors including heat map and GO terms.
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